Quince Therapeutics Receives Dual Nasdaq Delisting Notices for Bid Price and Market Value Deficiencies
QNCX is trading near its 52-week low of $0.08 (8.9% above the low) on light trading volume (0.2× avg).
Summary
Quince Therapeutics, Inc. has received notices from Nasdaq regarding non-compliance with both the minimum $1.00 bid price and $50 million market value of listed securities requirements, initiating a 180-day period to regain compliance and avoid potential delisting.
Key Events · Corporate Governance and Compliance · QNCX
-
Received Nasdaq Bid Price Notice
On March 16, 2026, the company received a notice from Nasdaq for non-compliance with the $1.00 minimum bid price rule (Listing Rule 5450(a)(1)) for 30 consecutive business days.
-
Received Nasdaq Market Value of Listed Securities (MVLS) Notice
On March 17, 2026, the company received a notice from Nasdaq for non-compliance with the $50 million MVLS requirement (Listing Rule 5450(b)(2)(A)) for 30 consecutive business days.
-
180-Day Compliance Period Initiated
The company has a period of 180 calendar days, until September 14, 2026, to regain compliance with both the Minimum Bid Price and MVLS Requirements.
-
Potential Delisting Risk
Failure to regain compliance could result in delisting from the Nasdaq Global Select Market, though the stock will continue to trade during the compliance period.
Analysis · QNCX · Life Sciences
Quince Therapeutics, Inc. faces a critical challenge to maintain its Nasdaq listing, having received notices for failing to meet both the minimum $1.00 bid price and the $50 million market value of listed securities requirements. With a current stock price of $0.0871 and a market cap of approximately $4.45 million, the company is significantly below both thresholds. Regaining compliance within the 180-day period will likely necessitate a reverse stock split to address the bid price and a substantial increase in valuation to meet the market value requirement, or a transfer to the Nasdaq Capital Market. Failure to comply could lead to delisting, which would severely impact the company's liquidity and investor confidence.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNCX was trading at $0.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.08 to $4.55. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.